Company

We strive to make unique discoveries

“t is a good workplace with a great atmosphere. Social cohesion is emphasized – also in practice.”
Ronni Refstrup Hansen, Senior Scientist, Drug Substance Development

Symphogen is the Antibody Center of Excellence in the Servier Group. We apply our highly efficient antibody platform and capabilities in the discovery and early development of differentiated antibody therapeutics.

We were founded in 2000 and became part of the Servier Group in June 2020 to support Servier’s commitment to improve patient’s health and the R&D strategy within oncology and immune oncology.

Servier, a global pharmaceutical group

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. 

A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. 

Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). 

Please see servier.com for more information.